Bioventus Inc (BVS)

NASDAQ

Currency in USD

7.510

-0.130(-1.70%)

Real-time Data·17:11:41

Fair Value

Unlock Value

Day's Range

7.460

7.740

52 wk Range

5.810

14.380

BVS Financial Summary

A brief financial summary of Bioventus Inc as well as the most significant critical numbers from each of its financial reports. In addition, some financial ratios derived from these reports are featured. Users can opt to see 4 periods of either annual or quarterly information.

Key Ratios

P/E Ratio263.98

Price/Book3.03

Debt / Equity179.16%

Return on Equity1.39%

Dividend Yield0.00%

EBITDA58.98M

Fair ValueUnlock

Fair Value UpsideUnlock

Statements Highlights

Period Ending:

2013

31/12

2014

31/12

2015

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

2024

31/12

Income Statement

Total Revenues

aa.aa

321.16

430.9

512.12

512.35

573.28

Gross Profit

aa.aa

233.52

302.71

331.08

328.19

388.23

Operating Income

aa.aa

21.8

21.05

-34.66

2.03

39.84

Net Income

aa.aa

16.41

19.38

-158.7

-156.23

-33.54

Balance Sheet

Total Assets

aa.aa

494.47

1,225.86

1,372.65

810.91

727.96

Total Current Liabilities

aa.aa

122.59

180.86

304.02

175.5

210.4

Total Equity

aa.aa

144.16

533.79

412.22

221.12

185.6

Cash Flow

Levered Free Cash Flow

aa.aa

52.53

-25.11

92.14

-108.45

67.03

Cash from Operations

aa.aa

71.8

22.99

-13.54

15.34

38.8

Cash from Investing

aa.aa

-20.5

-283.76

-116.44

15.81

22.96

Cash from Financing

aa.aa

-29.57

273.37

62.08

-26.65

-54.58

Net Change in Cash

aa.aa

22.32

12.37

-67.38

5.13

4.62

* In Millions of USD (except for per share items)

Analyst Ratings

3 Buy

1 Hold

0 Sell

Ratings:

4 analysts

Overall Consensus

Strong Buy

Analysts 12-Month Price Target:

Average 12.750

(+69.77% Upside)

Earnings

Latest Release

Aug 06, 2025

EPS / Forecast

0.21 / 0.21

Revenue / Forecast

147.70M / 146.28M

EPS Revisions

Unlock

Last 90 days

FAQ

What were Bioventus's earnings for the latest quarter?

The Bioventus EPS (TTM) is 0.03. Bioventus reported sales of 147.66, net income of 7.46, and EPS of 0.21 for the latest quarter.

What was Bioventus's net income for the latest quarter?

Bioventus's net income for the latest quarter was 7.46.

How did Bioventus's performance compare year-over-year in the latest quarter?

The company's revenue moved from 123.88 in the previous quarter to 147.66 in the latest quarter, and net income moved from -2.64 to 7.46 compared to the previous quarter.

What is Bioventus's net profit margin on a TTM basis?

Bioventus's trailing twelve months (TTM) net profit margin is -5.85%.

How does Bioventus's debt to equity ratio compare to industry standards?

Bioventus's total debt-to-equity ratio is 179.16%.

What is Bioventus's return on investment on a TTM basis?

Bioventus's trailing twelve months (TTM) return on investment (ROI) is 1.39%.

Did Bioventus gain or lose cash last quarter?

In the latest quarter, Bioventus's net change in cash was 10.11 million.

What were Bioventus's total assets and liabilities in the latest quarter?

As of the latest quarter, Bioventus reported total assets of 706.79 million and total liabilities of 185.68 million.

How has Bioventus's total revenue grown this year?

Bioventus's total revenue was 123.88 in the previous quarter and 147.66 in the latest quarter.

What is Bioventus's gross margin on a TTM basis?

Bioventus's trailing twelve months (TTM) gross margin is 67.60%.

What was Bioventus's revenue per share for the latest quarter?

Bioventus's revenue per share for the latest quarter was 31.79.

NSE 30

5,152.99

+13.06

+0.25%

NSE All Share

141,439.75

+435.61

+0.31%

US 30

45,395.50

-236.2

-0.52%

US 500

6,463.60

-3.3

-0.05%

FTSE 100

9,321.40

+12.20

+0.13%

DAX

24,261.59

-101.50

-0.42%

South Africa Top 40

95,329.31

+262.45

+0.28%

Market Movers

Name	Last	Chg. %	Vol.
Fcmb	10.900	-0.91%	105.13M
Guaranty Trust Holding	96.05	+2.18%	25.00M
Access Holdings	27.45	+1.67%	15.69M
UBA	47.95	0.00%	14.23M
Zenith Bank	70.00	0.00%	10.18M
Aradel Holdings	510.00	-1.73%	2.66M
Julius Berger	146.10	+9.93%	2.15M

Name	Last	Chg. %	Vol.
Julius Berger	146.10	+9.93%	2.15M
Cutix	3.900	+9.86%	2.13M
Regal Insurance	1.47	+9.70%	15.85M
Veritas Kapital	2.17	+9.60%	59.57M
McNichols	3.50	+9.38%	677.72K
Nem	28.950	+8.83%	529.28K
Universal Insurance PLC	1.32	+8.20%	34.40M

Name	Last	Chg. %	Vol.
University Pre	5.540	-12.06%	681.46K
Cadbury Nig	57.85	-9.61%	660.41K
Abbey Mortgage Bank	6.55	-8.39%	254.88K
Daarcomm	1.12	-7.44%	3.04M
Austin Laz	2.71	-6.55%	2.59M
Mecure Industries	19.50	-6.02%	421.01K
Tantalizers	2.50	-5.66%	4.86M

Trending Stocks

Name	Last	Chg. %	Vol.
Mutual Benefits Assurance	4.45	+1.14%	18.05M
MTN Nigeria	435.00	0.00%	707.31K
Aiico	4.47	+6.94%	26.20M
Dangote Cement	520.00	0.00%	111.45K
Betaglas	449.35	0.00%	142.48K

Most Undervalued Stocks

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaaaa	5,379.30	+46.90%	7,902.19
Aaa Aaaaaaaaaa	520.00	+35.88%	706.58
Aa Aaaaaaaaaaaa	151.80	+31.85%	200.15
A Aaaa	1,890.00	+30.65%	2,469.28
A Aaaaaa	70.20	+18.13%	82.93
Aaaaaaaaaa Aaaa	640.00	+17.25%	750.40

Name	Last	Upside	Fair Value
Aaaaaaaaaaaaaaa	5,379.30	+46.90%	7,902.19
Aaa Aaaaaaaaaa	520.00	+35.88%	706.58
Aa Aaaaaaaaaaaa	151.80	+31.85%	200.15
A Aaaa	1,890.00	+30.65%	2,469.28
A Aaaaaa	70.20	+18.13%	82.93
Aaaaaaaaaa Aaaa	640.00	+17.25%	750.40

See full list

Install Our AppScan QR code to install app

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers

Popular Searches

Please try another search

Bioventus Inc (BVS)

BVS Financial Summary

Key Ratios

Statements Highlights

Analyst Ratings

Analysts 12-Month Price Target:

Earnings

FAQ

What were Bioventus's earnings for the latest quarter?

What was Bioventus's net income for the latest quarter?

How did Bioventus's performance compare year-over-year in the latest quarter?

What is Bioventus's net profit margin on a TTM basis?

How does Bioventus's debt to equity ratio compare to industry standards?

What is Bioventus's return on investment on a TTM basis?

Did Bioventus gain or lose cash last quarter?

What were Bioventus's total assets and liabilities in the latest quarter?

How has Bioventus's total revenue grown this year?

What is Bioventus's gross margin on a TTM basis?

What was Bioventus's revenue per share for the latest quarter?

Trending Stocks